Photo Credit: iStock.com/vadimguzhva
The ADA’s 85th Scientific Sessions will highlight breakthroughs in obesity and diabetes care, including GLP-1 therapies, tech advances, and prevention tools.
The upcoming American Diabetes Association (ADA) 85th Scientific Sessions will offer an in-depth look at obesity medications, nutritional interventions, and diabetes prevention and management. The event will convene more than 11,000 global researchers, clinicians, and industry leaders to highlight major strides in research and real-world treatment.
Per a press release by the ADA, attendees can expect to see clinical research showcasing the latest innovations in obesity care. The sessions will spotlight new data on GLP-1-based therapies, such as semaglutide and tirzepatide, and their role not only in glycemic control but also in cardiovascular health and peripheral artery disease.
“Roughly 42% (109.9 million) of American adults are living with obesity,” the ADA says. “In fact, obesity is linked to 30–53% of new diabetes cases in the US yearly and continues to rise.”
The meeting will also feature new insights on beta cell therapy for patients with type 1 diabetes. New findings will showcase technologies like predictive models and machine learning algorithms, and emerging companies have been invited to attend the Innovation Challenge on Saturday, June 21, to pitch their latest ideas on how to improve diabetes care.
Additional session tracks will address maternal health, nutrition science, and early risk monitoring.
“As we kick off the 85th Scientific Sessions, we’re proud to present a program that highlights our ongoing commitment to tackling the complex challenges of diabetes,” said Rita Rastogi Kalyani, MD, MHS, the ADA’s president of medicine and science. “This year’s agenda showcases our dedication to pushing the boundaries of research, encouraging innovation, and ultimately enhancing the lives of people living with diabetes and obesity. We anticipate a dynamic and meaningful event that will inspire progress and shape the future of diabetes care, especially during this critical era of therapeutic and technological breakthroughs.”
The meeting will take place at the McCormick Place Convention Center in Chicago, running from June 20 to June 23, 2025. In addition to the in-person gathering, on-demand access will be available from June 25 to August 25.
More information and registration details are available at https://professional.diabetes.org/scientific-sessions.
Create Post
Twitter/X Preview
Logout